STING-IN-16 是一种 STING 抑制剂,对人源和鼠源 STING 抑制的 IC50 值分别为 44 nM 和 32 nM,可有效抑制人源细胞和小鼠细胞中 STING 轴的激活,恢复肾脏线粒体功能,抑制活性氧 (ROS) 生成并减少细胞凋亡 (apoptosis),显示出显著的体内抗炎效果,可用于自身免疫和自身炎症性疾病的研究。
产品编号: MS-K71352 CAS No.: 2982807-58-7 分子式: C25H22ClN3O2 分子量: 431.91
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

STING-IN-16 是一种 STING 抑制剂,对人源和鼠源 STING 抑制的 IC50 值分别为 44 nM 和 32 nM,可有效抑制人源细胞和小鼠细胞中 STING 轴的激活,恢复肾脏线粒体功能,抑制活性氧 (ROS) 生成并减少细胞凋亡 (apoptosis),显示出显著的体内抗炎效果,可用于自身免疫和自身炎症性疾病的研究。

生物实验数据

生物活性 STING-IN-16 is a STING inhibitor with IC50 values of 44 nM (human) and 32 nM (mouse) for STING inhibition, effectively suppresses STING axis activation in human and mouse cells, restores renal mitochondrial function, inhibits reactive oxygen species (ROS) production, and reduces apoptosis, demonstrating significant in vivo anti-inflammatory effects, and can be used for research on autoimmune and autoinflammatory diseases.
体外研究
(In Vitro)

STING-IN-16 (Compound 5c) (1 μM, 24 h) 抑制 STING的激活,IC50 分别为 44 nM (THP1-Blue-ISG) 和 32 nM (RAW-Lucia-ISG 细胞)。
STING-IN-16 (0.3-3 μM, 3-6 h) 抑制 THP1 细胞、骨髓来源巨噬细胞 (BMDM)、小鼠胚胎成纤维细胞 (MEF)和小鼠巨噬细胞 (RAW264.7) 中 STING 激动剂诱导的 STING 信号激活并显著提高 STING 的热稳定性。
STING-IN-16 (1 μM, 6 h) 抑制 HK2 细胞中由 Cisplatin (MS-E94993) 诱导的 DNA 损伤触发的 cGAS-STING 轴激活,从而减少 ROS 积累和细胞凋亡。

Western Blot Analysis

Cell Line: THP1 cells, BMDM cells, HK2 cells
Concentration: 0.3, 1, 3 μM
Incubation Time: 6 h
Result: Inhibited MSA-2 (MS-P73760)-stimulated phosphorylation of STING, TBK1, and IRF3, showing better activity than H151(MS-H85738) in THP1 cells.
Inhibited Vadimezan (DMXAA) (MS-C33508)-stimulated phosphorylation of STING, TBK1, and IRF3, showing better activity than H151 in BMDM cells.
Inhibited cisplatin-stimulated phosphorylation of STING, TBK1, IRF3, and P65, exhibiting higher potency than H151 in HK2 cells.
Decreased the expression of apoptosis markers such as cleaved-caspase3, cleaved-caspase8, and DNA damage markers (γ-H2A.X and p-CHK1).

Real Time qPCR

Cell Line: THP1 cells, BMDM cells, HK2 cells
Concentration: 0.3, 1, 3 μM
Incubation Time: 3, 6 h
Result: Inhibited MSA-2-triggered gene expression of the cytokines (ISG15, ISG56, IFNβ, CXCL10 and CCL5) dose-dependently in THP1 cells.
Inhibited DMXAA-triggered gene expression of the cytokines (ISG15, ISG56, IFNβ, CXCL10 and CCL5) dose-dependently in BMDM cells.
Inhibited diABZI STING agonist-1 (MS-L39523), cGAMP (MS-E89081) and HTDNA-triggered gene expression of the cytokines ( IFNβ, IL6, CXCL10 and ISG15) in THP1 cells and BMDM cells.
Reduced cisplatin-induced gene expression of inflammatory cytokines such as IL6, TNFA, IL8 and CXCL10 in HK2 cells.

ELISA Assay

Cell Line: THP1 cells, BMDM cells
Concentration: 0.3, 1, 3 μM
Incubation Time: 6 h
Result: Decreased MSA-2-induced secretion of IFN-β, CXCL10, and IL-6, showing considerably higher potency than H151 in THP1 cells.
Decreased DMXAA-induced secretion of IFN-β, CXCL10, and IL-6, showing considerably higher potency than H151 in BMDM cells.

Cell Viability Assay

Cell Line: HK2 cells
Concentration: 1 μM
Incubation Time: 6 h
Result: Attenuated Cisplatin-induced cell death.
体内研究
(In Vivo)

STING-IN-16 (Compound 5c) (10 mg/kg,腹腔注射,每日一次,持续 3 天) 缓解小鼠中 Cisplatin (顺铂) (MS-E94993) 诱导的炎症。
STING-IN-16 (10 mg/kg,腹腔注射,单次剂量) 在 MSA-2 诱导的炎症小鼠模型中显示出抗炎效果。

Animal Model: Cisplatin-induced kidney injury C57BL/6 male mice (8 weeks)
Dosage: 10 mg/kg
Administration: i.p. daily for 3 days
Result: Blocked the expression of Ifnb, Il6, and Tnfa.
Reduced cisplatin-induced BUN elevation.
Alleviated cisplatin-induced pathological changes (severe tubular dilation, tubular necrosis, and cast formation).
Reduced cisplatin-induced elevation of plasma IL-6, which was better than that of H151.
Restored the expression of such mitochondria-encoded genes(mt-CO1, mt-CO2, mt-CO3, mt-ATP6, mt-ND2 and mt-ND4).
Animal Model: MSA-2-induced inflammation C57BL/6 male mice (8 weeks)
Dosage: 10 mg/kg
Administration: i.p. for a single dose
Result: Decreased MSA-2-induced cytokines secretion in serum, including IFN-β, CXCL10, and IL-6.
Diminished MSA-2-induced expression of Ifnb and Il6 in the kidney tissue.
Lowered MSA-2-stimulated expression of Ifnb, Il6, and Ccl5 in the heart tissue.

化学信息

分子量 431.91
分子式 C25H22ClN3O2
CAS No. 2982807-58-7

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础